VJHemOnc is committed to improving our service to you

ASH 2019 | Prevention of progression: ixazomib/len/dex in high-risk SMM

VJHemOnc is committed to improving our service to you

Irene Ghobrial

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase 2 trial aimed to determine the progression-free survival and response rate of early therapeutic intervention in patients with high-risk smoldering multiple myeloma (SMM) using the combination of ixazomib, lenalidomide and dexamethasone. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter